| Autor: |
Maicon Falavigna, Karlyse Claudino Belli, Alexandre Naime Barbosa, Alexandre Prehn Zavascki, Ana Catharina de Seixas Santos Nastri, Christiane Machado Santana, Cinara Stein, Débora Dalmas Gräf, Flavio Adsuara Cadegiani, Hélio Penna Guimarães, José Tadeu Monteiro, Juliana Carvalho Ferreira, Luciano Cesar Pontes de Azevedo, Marcelo Mihailenko Chaves Magri, Marcone Lima Sobreira, Maria Beatriz Gandra de Souza Dias, Maura Salaroli de Oliveira, Mirian de Freitas Dal Ben Corradi, Regis Rosa, Ricardo Souza Heinzelmann, Rosemeri Maurici da Silva, Rubens Belfort Junior, Sergio Cimerman, Verônica Colpani, Viviane Cordeiro Veiga, Carlos Roberto Ribeiro de Carvalho |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Brazilian Journal of Infectious Diseases, Vol 26, Iss 2, Pp 102347- (2022) |
| Druh dokumentu: |
article |
| ISSN: |
1413-8670 |
| DOI: |
10.1016/j.bjid.2022.102347 |
| Popis: |
ABSTRACT: Background: Several therapies have been used or proposed for the treatment of COVID-19, although their effectiveness and safety have not been properly evaluated. The purpose of this document is to provide recommendations to support decisions about the drug treatment of outpatients with COVID-19 in Brazil. Methods: A panel consisting of experts from different clinical fields, representatives of the Brazilian Ministry of Health, and methodologists (37 members in total) was responsible for preparing these guidelines. A rapid guideline development method was used, based on the adoption and/or adaptation of recommendations from existing international guidelines combined with additional structured searches for primary studies and new recommendations whenever necessary (GRADE-ADOLOPMENT). The rating of quality of evidence and the drafting of recommendations followed the GRADE method. Results: Ten technologies were evaluated, and 10 recommendations were prepared. Recommendations were made against the use of anticoagulants, azithromycin, budesonide, colchicine, corticosteroids, hydroxychloroquine/chloroquine alone or combined with azithromycin, ivermectin, nitazoxanide, and convalescent plasma. It was not possible to make a recommendation regarding the use of monoclonal antibodies in outpatients, as their benefit is uncertain and their cost is high, with limitations of availability and implementation. Conclusion: To date, few therapies have demonstrated effectiveness in the treatment of outpatients with COVID-19. Recommendations are restricted to what should not be used, in order to provide the best treatment according to the principles of evidence-based medicine and to promote resource savings by aboiding ineffective treatments. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
